Danvatirsen
As of the edition of 20 October 2026, Danvatirsen is an oligonucleotide: stopped in 2025; acts on STAT3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Oligonucleotide
- Registered trials
- 15, 2 stopped early
- Disease areas
- Cancer; Blood and lymph; Lungs and airways; Digestive system; Immune system; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Danvatirsen.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| STAT3 | Signal transducer and activator of transcription 3 | P40763 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 8 | 5 | 3 | 0 |
| Phase 2 | 7 | 3 | 2 | 2 |
| All trials | 15 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Akcea Therapeutics | Lead sponsor of trials | 2012 to now |
| AstraZeneca | Lead sponsor of trials | 2013 to now |
| Acerta Pharma | Lead sponsor of trials | 2018 to now |
| Flamingo Therapeutics | Lead sponsor of trials | 2023 to now |